KINTOR PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL OF GT20029 FOR TREATMENT OF ANDROGENETIC ALOPECIA IN CHINA REACHED PRIMARY ENDPOINT
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
KINTOR PHARMA-B: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
KINTOR PHARMA-B: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL OF KX-826 AND MINOXIDIL COMBINATION THERAPY FOR THE TREATMENT OF MALE AGA RECEIVED CLEARANCE BY CHINA NMPA
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE BY CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
KINTOR PHARMA-B: INSIDE INFORMATION RESULTS OF KX-826 PHASE III CLINICAL TRIAL FOR TREATMENT OF MALE AGA IN CHINA
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
KINTOR PHARMA-B: Notification Letter to Non-registered holders - Notice of Publication of 2023 Interim Report and Request Form
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL OF GT20029 FOR TREATMENT OF ANDROGENETIC ALOPECIA IN CHINA
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT ENROLLMENT IN LONG-TERM SAFETY PHASE III TRIAL OF KX-826 FOR TREATMENT OF AGA
KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
No Data